Explainer
RSV explained: who is at risk, the season and prevention options
Respiratory syncytial virus (RSV) is one of the most common causes of chest infections in young children worldwide and also causes serious illness in older adults.[1] Infants under 6 months face the highest risk, and in temperate countries the virus circulates mainly in late autumn and winter.[2][3] Since 2023, regulators have approved vaccines for older adults and for use in pregnancy, plus long-acting antibodies for babies.[4][5][6][7]
This page is general information, not medical advice. Talk to a doctor, nurse, midwife or pharmacist about whether an RSV vaccine or infant antibody is right for you or your child, and follow your national health agency’s guidance. We do not give doses or schedules. If a baby is struggling to breathe or turning blue or grey, call your local emergency number.
Respiratory syncytial virus (RSV) is one of the most common causes of lower respiratory infections in children around the world, and it also causes a substantial burden of severe disease in older people.[1] WHO estimates that it causes over 3.6 million hospitalisations and about 100,000 deaths a year in children under 5, with 97% of those deaths in low- and middle-income countries.[8] Since 2023, US regulators have approved several new vaccines and infant antibodies to prevent severe RSV, and agency recommendations differ.[4][6][7]
What RSV is and how it spreads
RSV is a common respiratory virus. Almost every child catches it by their second birthday, and people catch it again later in life, usually with milder illness.[9] It spreads through the air when an infected person coughs or sneezes, and probably also through touch and contaminated surfaces.[10] Symptoms usually appear 4 to 7 days after exposure.[11]
RSV spreads through infectious respiratory particles and is also thought to spread by direct contact and contaminated surfaces.[10] Primary infection is near-universal by age 2, and reinfection is common throughout life; it is usually mild except in older adults and people with significant underlying illness.[9] WHO notes that early-life RSV lower respiratory tract infection may be followed by repeat hospitalisation, recurrent wheeze or asthma and impaired lung health, and that in older adults it can worsen chronic lung and heart disease.[12]
Symptoms and who gets seriously ill
The NHS says most people with RSV only get cold-like symptoms, and babies may also be irritable and feed less than usual.[13] In babies, RSV is a common cause of bronchiolitis, a chest infection, and it can cause pneumonia in babies and older adults.[14] WHO notes that some young children with RSV do not have a fever.[15]
WHO says infants, especially those under 6 months, face the highest risk of severe disease and death, and about half of child RSV deaths happen in that age group.[2] Global estimates for adults do not exist. In the US, RSV has been estimated to cause up to 160,000 hospitalisations and 10,000 deaths a year among adults over 65, and hospitalisation rates are higher in people with asthma, COPD or congestive heart failure.[16]
There is no specific treatment for RSV. Severe cases are managed with supportive care such as fluids and oxygen.[17] The NHS says to call 999 if a child is struggling to breathe (grunting, long pauses, or the tummy sucking in under the ribs), if someone is floppy and will not wake or stay awake, or if lips or skin turn very pale, blue or grey.[18] It advises an urgent GP appointment or NHS 111 if a child is feeding much less than normal or has had a dry nappy for 12 hours or more, or if an adult with a long-term condition or weakened immune system gets cold symptoms.[19]
When RSV season happens
WHO says RSV causes seasonal epidemics in temperate climates, usually in late autumn and winter, with raised circulation lasting about five months on average. Many tropical and sub-tropical countries also have consistent high months but no clear seasonal pattern.[3] The FDA says RSV in most of the US typically starts in the autumn and peaks in winter.[20] US guidance therefore times infant antibodies to the season: CDC guidance and the American Academy of Pediatrics both point to October through March for most of the country.[21] Simple hygiene also helps: the NHS suggests cleaning toys and surfaces, using and binning tissues, and keeping newborns away from people with colds or flu.[22] For flu, which peaks in the same months, see flu explained and the 2026-27 flu season tracker.
Prevention products and who they are for
WHO counts three licensed products for young infants (two long-acting monoclonal antibodies given soon after birth and one maternal vaccine) and three vaccines for older people and adults with certain underlying illnesses.[23]
Vaccines for older adults. The US approved its first RSV vaccine, GSK’s Arexvy, in May 2023 for adults 60 and older; Pfizer’s Abrysvo was approved for the same age group that month.[4][5] Moderna’s mRNA vaccine mRESVIA followed in 2024.[24] The NHS says older adults need only one dose, which should protect them for several years.[25]
A vaccine in pregnancy. Vaccinating during pregnancy passes antibodies through the placenta, protecting the baby for about 6 months after birth.[26]
An antibody for the baby. A long-acting antibody injection gives the baby ready-made protection for its first RSV season. The two approved in the US are nirsevimab (Beyfortus) and clesrovimab (Enflonsia).[6][7] Most babies need either the pregnancy vaccine or the antibody, not both.[27]
Older adults. The FDA approved Arexvy on 3 May 2023 and Abrysvo for adults 60 and older the same month; mRESVIA was approved for adults 60 and older in 2024 and extended to at-risk adults aged 18 to 59 in June 2025.[4][5][24][28] The NHS notes that, very rarely, older adults may develop Guillain-Barré syndrome after RSV vaccination.[29]
Maternal vaccine. The FDA approved Abrysvo for pregnancy on 21 August 2023 with a 32-to-36-week window on the US label, while WHO recommends vaccination from 28 weeks in most settings.[5][26] In the randomised placebo-controlled trial, it cut severe RSV lower respiratory tract disease in infants by 81.8% within 90 days of birth and 69.4% within 180 days.[30] The label warns of a numerical imbalance in preterm births (5.7% versus 4.7% with placebo); the FDA said the data could neither establish nor exclude a causal link.[31]
Infant monoclonal antibodies. The FDA approved nirsevimab on 17 July 2023; in randomised trials it cut medically attended RSV lower respiratory tract infection by about 70% in preterm infants and 75% in term and late-preterm infants versus placebo.[6][32] Clesrovimab was approved on 9 June 2025; in Merck’s placebo-controlled CLEVER trial it reduced medically attended RSV lower respiratory infections by 60.5% and RSV hospitalisations by 84.3% through day 150, as reported by the company.[7][33] To read these figures, see how clinical trials work.
What agencies recommend in 2026
Recommendations differ by country and have shifted in the US.
- WHO says the antibody can be given to all newborns and infants entering their first season, and that countries could consider it for high-risk children up to 24 months entering a second season.[34] It notes the products are too expensive for most low- and middle-income countries; a Gavi-supported maternal vaccine programme is expected in 2026–2030, depending on funding.[35]
- US CDC guidance, last updated in August 2025, recommends RSV vaccines for all adults 75 and older and for adults 50 to 74 at increased risk.[36] For infants under 8 months entering their first season, it recommends nirsevimab or clesrovimab if the mother was not vaccinated in pregnancy or her status is unknown.[37] Under the childhood schedule HHS issued in January 2026, however, RSV immunisation for children is listed for high-risk groups or shared clinical decision-making rather than for all children.[38] Medical groups including the AAP opposed that change.[39]
- American Academy of Pediatrics. Its 2026-27 guidance, published on 2 September 2026, still recommends immunisation for all infants under 8 months entering their first season unless they are protected by maternal vaccination, and widens high-risk criteria for children aged 8 to 19 months in their second season.[40]
- UK NHS offers a free vaccine from 28 weeks of pregnancy, to people 75 and over, to people aged 65 to 74 with a weakened immune system or long-term lung condition, and to older care-home residents.[41] Unlike flu vaccines, it is given all year round.[25]
Recommendations change between seasons and countries. Check the current guidance from your national health agency and ask a clinician which option applies to you. For the agencies themselves, see the pages on the World Health Organization, the US Centers for Disease Control and Prevention and the US Food and Drug Administration.
The World Health Organization publishes the global RSV burden estimates used above.[8] In the US, the FDA approves RSV products and the CDC issues immunisation guidance.[4][36]
Read next
Next in the crash course
Measles explained: symptoms, MMR vaccine and elimination status
What measles is, how it spreads, its complications, how well the MMR vaccine works, and why Canada lost and the US risks losing elimination status.
Questions readers ask
Is RSV just a cold?
For most people, yes. The NHS says most people only get cold-like symptoms. But RSV is a common cause of bronchiolitis in babies and can cause pneumonia in babies and older adults.[13][14]
Who is most at risk from RSV?
WHO says infants, especially those under 6 months, are at the highest risk of severe disease and death. Older people and those with significant underlying illnesses can also become severely ill.[2][9]
When is RSV season?
In temperate climates, WHO says RSV epidemics tend to occur in late autumn and winter, with raised circulation lasting about five months. The FDA says US circulation typically starts in the autumn and peaks in winter.[3][20]
Is there a treatment for RSV?
There is no specific treatment. WHO says severe cases are managed with supportive care such as fluids and oxygen, and the NHS says RSV often gets better on its own in 1 or 2 weeks.[17]
Sources
· 41 claims from 10 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
WHO describes respiratory syncytial virus (RSV) as one of the most common causes of acute lower respiratory infections in children worldwide, and a cause of substantial severe respiratory disease in older people. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [2]
WHO says infants, especially those under 6 months, are at the highest risk of severe RSV disease and death, and about half of child RSV deaths occur in infants under 6 months. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Overview (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Scope of the problem (retrieved 2026-11-07)
- [3]
WHO says RSV causes seasonal epidemics in temperate climates, usually in late autumn and winter, with elevated circulation lasting about five months on average; most tropical and sub-tropical countries also have consistent high-circulation months but no clear seasonality. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Seasonality (retrieved 2026-11-07)
- [4]
On 3 May 2023 the FDA approved GSK's Arexvy, the first RSV vaccine approved in the US, for adults 60 and older. confirmedas of 2023-05-03
- FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine · US Food and Drug Administration · Primary source · 2023-05-03 (retrieved 2026-11-07)
- [5]
On 21 August 2023 the FDA approved Pfizer's Abrysvo as the first vaccine for use in pregnancy to protect infants from RSV lower respiratory tract disease from birth to 6 months; the label specifies 32 through 36 weeks of pregnancy, and Abrysvo had been approved in May 2023 for adults 60 and older. confirmedas of 2023-08-21
- FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants · US Food and Drug Administration · Primary source · 2023-08-21 (retrieved 2026-11-07)
- FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants · US Food and Drug Administration · Primary source · 2023-08-21 (retrieved 2026-11-07)
- [6]
On 17 July 2023 the FDA approved Beyfortus (nirsevimab) to prevent RSV lower respiratory tract disease in newborns and infants in their first RSV season, and in children up to 24 months who remain vulnerable through their second season. confirmedas of 2023-07-17
- FDA Approves New Drug to Prevent RSV in Babies and Toddlers · US Food and Drug Administration · Primary source · 2023-07-17 (retrieved 2026-11-07)
- [7]
On 9 June 2025 the FDA approved Merck's Enflonsia (clesrovimab) to prevent RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season. confirmedas of 2025-06-09
- U.S. FDA Approves Merck's ENFLONSIA (clesrovimab-cfor) for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season · Merck (press release) · Primary source · 2025-06-09 (retrieved 2026-11-07)
- Merck's Clesrovimab (Enflonsia) Receives FDA Approval to Protect Infants From RSV During First Season · Contagion Live · Secondary source · 2025-06-09 (retrieved 2026-11-07)
- [8]
WHO estimates that RSV causes over 3.6 million hospitalisations and about 100,000 deaths a year in children under 5, with 97% of these child deaths in low- and middle-income countries. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [9]
WHO says almost all babies are infected with RSV by their second birthday, and older children and adults are often reinfected, usually with mild illness except in older people and those with significant underlying illness. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Transmission (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Transmission (retrieved 2026-11-07)
- [10]
WHO says RSV spreads through infectious respiratory particles in the air and is also thought to spread by direct contact or contaminated surfaces; the NHS says it spreads in the coughs and sneezes of someone who has it. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Transmission (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · How to avoid catching and spreading RSV (retrieved 2026-11-07)
- [11]
WHO says the first RSV symptoms usually appear 4 to 7 days after exposure. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Signs and symptoms (retrieved 2026-11-07)
- [12]
WHO says RSV lower respiratory infection in early life may lead to longer-term problems such as repeat hospitalisation, recurrent wheeze or asthma, and impaired lung health, and that in older adults RSV can worsen chronic lung and heart disease. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Signs and symptoms (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Signs and symptoms (retrieved 2026-11-07)
- [13]
The NHS says most people with RSV only get cold-like symptoms, and that babies may also be irritable and feed less than usual. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Symptoms of an RSV infection (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Symptoms of an RSV infection (retrieved 2026-11-07)
- [14]
The NHS says RSV is a common cause of bronchiolitis in babies and can cause pneumonia in babies and older adults. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Overview (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Overview (retrieved 2026-11-07)
- [15]
WHO notes that although most children with RSV have a fever, some young children may not. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Signs and symptoms (retrieved 2026-11-07)
- [16]
WHO says global estimates of adult RSV disease are not known, but in the US RSV has been estimated to cause up to 160,000 hospitalisations and 10,000 deaths a year among adults over 65, with higher hospitalisation rates in people with conditions such as asthma, COPD or congestive heart failure. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Scope of the problem (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Scope of the problem (retrieved 2026-11-07)
- [17]
WHO and the NHS say there is no specific treatment for RSV; severe cases are managed with supportive care such as fluids and oxygen, and the NHS says it often gets better on its own in 1 or 2 weeks. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Treatment (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Treatment for RSV infections (retrieved 2026-11-07)
- [18]
The NHS says to call 999 if a child has difficulty breathing (such as grunting, long pauses in breathing or the tummy sucking under the ribs), if someone is floppy and will not wake or stay awake, or if lips or skin turn very pale, blue or grey. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Immediate action required: Call 999 if (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Immediate action required: Call 999 if (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Immediate action required: Call 999 if (retrieved 2026-11-07)
- [19]
The NHS advises an urgent GP appointment or NHS 111 if a child is unwell and getting worse, is feeding much less than normal, or has had a dry nappy for 12 hours or more, or if an adult with a long-term condition or weakened immune system gets cold symptoms. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Urgent advice: Ask for an urgent GP appointment or get help from NHS 111 if (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Urgent advice: Ask for an urgent GP appointment or get help from NHS 111 if (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · Urgent advice: Ask for an urgent GP appointment or get help from NHS 111 if (retrieved 2026-11-07)
- [20]
The FDA says RSV circulation in most of the US is seasonal, typically starting in the autumn and peaking in winter. confirmedas of 2023-08-21
- FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants · US Food and Drug Administration · Primary source · 2023-08-21 (retrieved 2026-11-07)
- FDA Approves New Drug to Prevent RSV in Babies and Toddlers · US Food and Drug Administration · Primary source · 2023-07-17 (retrieved 2026-11-07)
- [21]
The AAP's 2026-27 guidance and CDC guidance both time infant RSV antibodies to October through March in most of the continental US. confirmedas of 2026-09-02
- AAP expands RSV immunization recommendations for high-risk children · Contemporary Pediatrics · Secondary source · 2026-09-02 (retrieved 2026-11-07)
- Clinical Guidance: RSV Immunization for Infants and Young Children · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- [22]
The NHS lists ways to reduce the spread of RSV, including cleaning toys and surfaces, using and binning disposable tissues, and keeping newborns away from people with colds or flu. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · How to avoid catching and spreading RSV (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) · NHS · Primary source · 2024-07-05 · How to avoid catching and spreading RSV (retrieved 2026-11-07)
- [23]
WHO says three licensed products protect young infants (two long-acting monoclonal antibodies given soon after birth and a maternal vaccine given late in pregnancy), and three vaccines are licensed to prevent severe RSV in older people and adults with certain underlying illnesses. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Key facts (retrieved 2026-11-07)
- [24]
The FDA approved Moderna's RSV vaccine mRESVIA effective 31 May 2024 for adults 60 and older. confirmedas of 2024-05-31
- MRESVIA BLA approval letter (replacement letter dated June 14, 2024) · US Food and Drug Administration · Primary source · 2024-06-14 (retrieved 2026-10-10)
- MRESVIA BLA approval letter (replacement letter dated June 14, 2024) · US Food and Drug Administration · Primary source · 2024-06-14 (retrieved 2026-10-10)
- [25]
The NHS says older adults need only one RSV vaccine dose, which should protect them for several years, while pregnant women should be vaccinated in every pregnancy; the vaccine is given all year round. confirmedas of 2026-11-07
- RSV vaccine · NHS · Primary source · 2024-09-01 · How the RSV vaccine is given (retrieved 2026-11-07)
- RSV vaccine · NHS · Primary source · 2024-09-01 · How the RSV vaccine is given (retrieved 2026-11-07)
- [26]
WHO recommends maternal RSV vaccination in the third trimester (from 28 weeks in most settings), which passes antibodies through the placenta and protects the baby for about 6 months after birth. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- [27]
CDC guidance says two immunisations are recommended to protect infants, a maternal vaccine (Pfizer's Abrysvo) given in pregnancy or an infant RSV antibody given after birth, and that most infants will not need both. confirmedas of 2025-08-18
- RSV Immunization Guidance · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- Clinical Guidance: RSV Immunization for Infants and Young Children · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- [28]
On 12 June 2025 the FDA extended mRESVIA's approval to adults aged 18-59 who are at increased risk of RSV lower respiratory tract disease. confirmedas of 2025-06-12
- MRESVIA supplement approval letter, June 12, 2025 · US Food and Drug Administration · Primary source · 2025-06-12 (retrieved 2026-10-10)
- MRESVIA (product page and approval history) · US Food and Drug Administration · Primary source (retrieved 2026-10-10)
- [29]
The NHS says the most common RSV vaccine side effects are mild and short-lived, and that very rarely older adults may develop Guillain-Barré syndrome after vaccination. confirmedas of 2026-11-07
- RSV vaccine · NHS · Primary source · 2024-09-01 · Side effects of the RSV vaccine (retrieved 2026-11-07)
- RSV vaccine · NHS · Primary source · 2024-09-01 · Side effects of the RSV vaccine (retrieved 2026-11-07)
- [30]
In the randomised, placebo-controlled trial reviewed by the FDA, Abrysvo given in pregnancy reduced the risk of severe RSV lower respiratory tract disease in infants by 81.8% within 90 days of birth and 69.4% within 180 days. confirmedas of 2023-08-21
- FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants · US Food and Drug Administration · Primary source · 2023-08-21 (retrieved 2026-11-07)
- [31]
The Abrysvo prescribing information warns of a numerical imbalance in preterm births in trial recipients (5.7% versus 4.7% with placebo); the FDA said the data were insufficient to establish or exclude a causal link. confirmedas of 2023-08-21
- FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants · US Food and Drug Administration · Primary source · 2023-08-21 (retrieved 2026-11-07)
- [32]
In the trials reviewed by the FDA, nirsevimab reduced the risk of medically attended RSV lower respiratory tract infection by about 70% in preterm infants and about 75% in term and late-preterm infants, compared with placebo. confirmedas of 2023-07-17
- FDA Approves New Drug to Prevent RSV in Babies and Toddlers · US Food and Drug Administration · Primary source · 2023-07-17 · Trial 03 (retrieved 2026-11-07)
- FDA Approves New Drug to Prevent RSV in Babies and Toddlers · US Food and Drug Administration · Primary source · 2023-07-17 · Trial 04 (retrieved 2026-11-07)
- [33]
In Merck's placebo-controlled Phase 2b/3 CLEVER trial in preterm and full-term infants, a single dose of clesrovimab reduced medically attended RSV lower respiratory infections by 60.5% and RSV-related hospitalisations by 84.3% through day 150 (about 5 months), as reported by Merck. confirmedas of 2025-06-09
- Merck's Clesrovimab (Enflonsia) Receives FDA Approval to Protect Infants From RSV During First Season · Contagion Live · Secondary source · 2025-06-09 (retrieved 2026-11-07)
- U.S. FDA Approves Merck's ENFLONSIA (clesrovimab-cfor) for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season · Merck (press release) · Primary source · 2025-06-09 (retrieved 2026-11-07)
- U.S. FDA Approves Merck's ENFLONSIA (clesrovimab-cfor) for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season · Merck (press release) · Primary source · 2025-06-09 · CLEVER trial results (the primary endpoint, medically attended lower respiratory infections, is given in the preceding paragraph as 60.5%) (retrieved 2026-11-07)
- [34]
WHO says the long-acting monoclonal antibody can be given to all newborns and infants entering their first RSV season, and that countries could consider it for high-risk children up to 24 months entering their second season. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- [35]
WHO says RSV prevention products are currently expensive and unaffordable for most low- and middle-income countries, and that a Gavi-supported maternal vaccine programme is expected to start in Gavi's 2026-2030 period, depending on funding. confirmedas of 2026-11-07
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · Prevention (retrieved 2026-11-07)
- Respiratory syncytial virus (RSV) fact sheet · World Health Organization · Primary source · WHO response (retrieved 2026-11-07)
- [36]
CDC guidance recommends RSV vaccines for all adults aged 75 and older and for adults aged 50 to 74 at increased risk of severe RSV. confirmedas of 2025-08-18
- RSV Immunization Guidance · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 · Page last updated 18 August 2025; also read via WebFetch (retrieved 2026-11-07)
- RSV Immunization Guidance · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 · Same sentence (the cached text keeps an – entity between 50 and 74) (retrieved 2026-11-07)
- [37]
CDC clinical guidance (last updated August 2025) recommends an infant RSV antibody, nirsevimab or clesrovimab, for infants younger than 8 months born during or entering their first RSV season if the mother did not receive an RSV vaccine in pregnancy or her status is unknown, given from October through March in most of the US. confirmedas of 2025-08-18
- Clinical Guidance: RSV Immunization for Infants and Young Children · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- Clinical Guidance: RSV Immunization for Infants and Young Children · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- Clinical Guidance: RSV Immunization for Infants and Young Children · US Centers for Disease Control and Prevention · Primary source · 2025-08-18 (retrieved 2026-11-07)
- [38]
Under the US childhood schedule HHS issued in January 2026, RSV immunisation for children is recommended for high-risk groups or through shared clinical decision-making rather than for all children. confirmedas of 2026-01-09
- HHS announces unprecedented overhaul of US childhood vaccine schedule · CIDRAP (University of Minnesota) · Secondary source · 2026-01-05 (retrieved 2026-10-11)
- The CDC Just Sidelined These Childhood Vaccines. Here's What They Prevent · NPR · Secondary source · 2026-01-09 (retrieved 2026-10-11)
- [39]
Medical groups including the American College of Physicians and the American Academy of Pediatrics opposed the January 2026 schedule change, and the AAP kept its own recommendations unchanged. confirmedas of 2026-01-09
- HHS announces unprecedented overhaul of US childhood vaccine schedule · CIDRAP (University of Minnesota) · Secondary source · 2026-01-05 (retrieved 2026-10-11)
- The CDC Just Sidelined These Childhood Vaccines. Here's What They Prevent · NPR · Secondary source · 2026-01-09 (retrieved 2026-10-11)
- [40]
In its 2026-27 guidance, published on 2 September 2026, the American Academy of Pediatrics continues to recommend RSV immunisation for all infants under 8 months born during or entering their first RSV season unless they are protected by maternal vaccination, and expands high-risk criteria for children aged 8 to 19 months entering their second season. confirmedas of 2026-09-02
- AAP Releases RSV Immunization Recommendations for 2026-2027 Season · American Academy of Pediatrics (HealthyChildren.org) · Primary source · 2026-09-02 (retrieved 2026-11-07)
- AAP expands RSV immunization recommendations for high-risk children · Contemporary Pediatrics · Secondary source · 2026-09-02 (retrieved 2026-11-07)
- [41]
The NHS offers a free RSV vaccine to people 28 weeks pregnant or more, people aged 75 or over, people aged 65 to 74 with a weakened immune system or long-term lung condition, and residents of care homes for older adults. confirmedas of 2026-11-07
- RSV vaccine · NHS · Primary source · 2024-09-01 · Who should have the RSV vaccine (retrieved 2026-11-07)
- RSV vaccine · NHS · Primary source · 2024-09-01 · Who should have the RSV vaccine (retrieved 2026-11-07)
- RSV vaccine · NHS · Primary source · 2024-09-01 · How to get the RSV vaccine (retrieved 2026-11-07)
Revision history (1)
- Page created.
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Mar 1, 2027.
Cite this page
"RSV explained: who is at risk, the season and prevention options." ContentLora, updated Nov 7, 2026. https://contentlora.com/explain/rsv-explained
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.